July Bonus Mid-Year Edition

July 2017 Bonus Mid-Year Edition

Volume 3, Issue 9

This bonus issue features conversations with families united by hematology, highlights from recent hematology/oncology meetings, and more.

Table of Contents

July 2017 Bonus Issue

CROs and Cons

Wednesday, July 12th, 2017
In his June 2017 Editor’s Corner (“Contract Research Agonizations”), ASH Clinical News’ Editor-in-Chief Mikkael Sekeres, MD, MS, called for an end to the bureaucratic...

Shouts & Mumblings: A Transplant in Every Kitchen

Wednesday, July 12th, 2017
“Patients with various blood-related cancers … receive transplants of bone marrow and peripheral blood stem cells to restore stem cells that were destroyed by...

Advocating for a Return to Common Sense in Clinical Research

Wednesday, July 12th, 2017
In his June 2017 Editor’s  Corner (“Contract Research Agonizations”), ASH Clinical News’ Editor-in-Chief Mikkael Sekeres, MD, MS, called for an end to the bureaucratic...

July 2017 Bonus Issue

ASH Co-Hosts Congressional Briefing on Sickle Cell Disease, Blood Journal’s Impact On the Rise,...

Wednesday, July 12th, 2017
ASH Co-Hosts Congressional Briefing on Sickle Cell DiseaseThe American Society of Hematology (ASH) co-hosted a congressional briefing on sickle cell disease (SCD) and gene...

Remembering H. Jean Khoury, NCI Funds Standardization of Cancer Genomic Data, and more

Wednesday, July 12th, 2017
Remembering H. Jean Khoury (1967-2017) H. Jean Khoury, MD, an expert in hematologic malignancies at the Winship Cancer Institute of Emory University, died at age...

July 2017 Bonus Issue

It Runs in the Blood

Wednesday, July 12th, 2017
For these doctors, hematology is “the family business” The term “family business” may conjure images of stores, restaurants, and other commercial enterprises, but it turns...

July 2017 Issue

What are treatment options for a patient with c-Myc positive diffuse large B-cell lymphoma?

Wednesday, July 12th, 2017
This month David Straus, MD, discusses treatment options for a patient with c-Myc positive diffuse large B-cell lymphoma. And don't forget to check out next...

July 2017 Issue

WIB_icon

Population-Based Study Finds Persistent Gaps in Understanding and Identification of VTE Risk

Wednesday, July 12th, 2017
An estimated 500,000 venous thromboembolism (VTE) events occur annually in the United States, about half of which are related to current or recent hospitalizations,...
WIB_icon

Isatuximab Plus Lenalidomide and Dexamethasone Active in Relapsed/Refractory Multiple Myeloma

Wednesday, July 12th, 2017
Treatment with the investigational anti-CD38 monoclonal antibody isatuximab (in combination with lenalidomide and dexamethasone) led to an overall response rate (ORR) of 51 percent...

Pembrolizumab Safe and Effective in Heavily Pretreated Patients With Classic Hodgkin Lymphoma

Wednesday, July 12th, 2017
Though the standard of care for patients with relapsed/refractory classic Hodgkin lymphoma (cHL) induces high rates of response, duration of response is estimated to...

FDA Accepts New Drug Application for CPX-351 for AML

Wednesday, July 12th, 2017
The FDA has accepted a new drug application (NDA) for CPX-351 – a liposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar...

Number of Physicians Who Own Their Own Practices Drops

Wednesday, July 12th, 2017
The AMA’s biannual practice survey shows that the proportion of physicians who have an ownership stake in their own practices fell to 47.1 percent...

AMA Considers Backing the Disclosure of Drug Prices on Consumer Ads

Wednesday, July 12th, 2017
Direct-to-consumer (DTC) advertising became legal in the United States in 1997 but has been debated ever since, with some groups claiming that this type...

NHLBI Announces New Funding Opportunities for Late-Stage Trials

Wednesday, July 12th, 2017
The National Heart, Lung, and Blood Institute (NHLBI) announced two new funding opportunities for late-stage, single- or multi-site, investigator-initiated clinical trials that address critical...

Are HCT Patients in Brazil at Increased Risk of Zika and Other Mosquito-Transmitted Infections?

Wednesday, July 12th, 2017
Since 2015, Brazil has experienced a triple epidemic of dengue, chikungunya, and Zika infections, putting the more than 2,000 hematopoietic cell transplantation (HCT) recipients...

Adding Eltrombopag to Immunosuppression Improves Hematologic Response in Patients With Severe Aplastic Anemia

Wednesday, July 12th, 2017
Acquired aplastic anemia (AA), which results from immune-mediated destruction of the bone marrow, can often be treated with immunosuppressive therapies. Whether the efficacy of...
WIB_icon

Clonal Hematopoiesis Almost “Inevitable” in Older Adults

Wednesday, July 12th, 2017
Using whole-genome sequencing (WGS) data, Florian Zink, from deCODE genetics/Amgen Inc. in Reykjavik, Iceland, and co-authors found that clonal hematopoiesis (CH) is highly prevalent...

July 2017 Issue

Evaluating a Risk-Adapted Treatment Approach in Younger Patients With AML

Wednesday, July 12th, 2017
A risk-adapted approach incorporating minimal residual disease (MRD) and cytogenetic data could help identify patients with acute myeloid leukemia (AML) who would benefit from...

Danazol Plus ATRA Safe and Effective in Corticosteroid- Resistant/Relapsed ITP

Wednesday, July 12th, 2017
According to results from a multicenter, prospective study presented at the 22nd Congress of the European Hematology Association, the combination of all-trans retinoid acid...

CC-122 Plus Obinutuzumab Effective in Relapsed/Refractory B-Cell NHL

Wednesday, July 12th, 2017
Combining the anti-CD20 monoclonal antibody obinutuzumab with the first-in-class pleiotropic pathway modifier CC-122 led to high response rates and durable remissions in patients with...

Updated Results From ZUMA-1 Show “Promising” Response Rates With CAR T-Cell Therapy in ...

Wednesday, July 12th, 2017
Treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a high objective response rate (ORR) in patients with relapsed/refractory non-Hodgkin...

Evaluating the Hedgehog Inhibitor Glasdegib in Patients With Heavily Pretreated Myelofibrosis

Wednesday, July 12th, 2017
In a phase Ib/II trial of patients with myelofibrosis whose disease did not respond to JAK inhibitors, treatment with the hedgehog inhibitor glasdegib did...

Forty Percent of Patients With Previously Treated IDH2-Mutated AML Respond to Enasidenib

Wednesday, July 12th, 2017
For the approximately 12 percent of patients with acute myeloid leukemia (AML) with the IDH2 mutation, the oral, selective, small-molecule inhibitor enasidenib could become...

Minimizing Toxicity, Predicting Efficacy With CD19 CAR T-Cell Therapy in B-Cell ALL

Wednesday, July 12th, 2017
Treatment with CD19-directed chimeric antigen receptor (CAR) T cells has induced high rates of complete response in adults with relapsed/refractory B-cell acute lymphocytic leukemia...

Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy Is Safe, Effective in Older Patients With ALL

Wednesday, July 12th, 2017
In February 2017, the U.S. Food and Drug Administration granted inotuzumab ozogamicin priority review for the treatment of adult patients with relapsed/refractory B-cell precursor...

Ublituximab Plus Ibrutinib Improves Objective Response Rates in High-Risk CLL

Wednesday, July 12th, 2017
Patients with chronic lymphocytic leukemia (CLL) and high-risk genetic mutations typically have a poor response to ibrutinib monotherapy. Adding ublituximab, a novel anti-CD20 monoclonal...

SHARE